Nebibeta (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. Simultaneously it stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide release that relaxes vascular smooth muscle. This dual action lowers systemic vascular resistance and blood pressure while preserving cardiac output.

The dose of Nebibeta is individualized by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration, following local prescribing guidelines and product labeling.

Safety of nebivolol during pregnancy or lactation has not been established, and it is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Nebibeta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older non‑selective β‑blockers, nebivolol offers high β1 selectivity and an additional nitric‑oxide‑mediated vasodilatory effect, which may result in better tolerability and a lower incidence of metabolic side effects. It is often chosen when a patient requires blood‑pressure control with minimal impact on lipid or glucose metabolism.

Nebibeta should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture, light and excessive heat. Do not store in a bathroom or near a heat source, and keep the container tightly closed when not in use.

Nebibeta is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless the product label specifically permits such modification.

The most serious adverse reactions include severe hypotension, marked bradycardia, heart block, and bronchospasm, especially in patients with underlying conduction disorders or reactive airway disease. Prompt medical attention is required if symptoms such as fainting, chest pain, severe shortness of breath, or swelling of the face occur.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia (heart rate <60 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or severe hepatic impairment. Consultation with a healthcare professional is essential before initiating therapy.